Why the study?
Are cerebral microbleeds associated with a clinically important increase in the risk of intracerebral haemorrhage in patients treated with thrombolytic or antithrombotic drugs?
Are cerebral microbleeds associated with a clinically important increase in the risk of intracerebral haemorrhage in patients treated with thrombolytic or antithrombotic drugs?
This review summarizes evidence on whether cerebral microbleeds indicate future intracerebral hemorrhage risk in stroke patients on antithrombotic or thrombolytic therapy.
Microbleeds should not yet alter antithrombotic decisions in stroke; leaves open their value for ICH risk stratification pending prospective data.
Cerebral microbleeds (CMBs) are an increasingly common neuroimaging finding in the context of ageing, cerebrovascular disease and dementia, with potentially important clinical relevance. Perhaps the most pressing clinical question is whether CMBs are associated with a clinically important increase in the risk of intracerebral haemorrhage (ICH), the most feared complication in patients treated with thrombolytic or antithrombotic (antiplatelet and anticoagulant) drugs. This review will summarize the evidence available regarding CMBs as an indicator of future ICH risk in stroke medicine clinical practice.
No takes yet. Share an insight, caveat, or question.
Kakar et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: